159
Participants
Start Date
October 26, 2017
Primary Completion Date
July 29, 2020
Study Completion Date
September 13, 2023
Pembrolizumab
IV infusion
Lismore Base Hospital ( Site 0402), Lismore
Southern Medical Day Care Centre ( Site 0408), Wollongong
Orange Health Services ( Site 0406), Orange
Royal Brisbane and Women s Hospital ( Site 0407), Herston
Princess Alexandra Hospital ( Site 0405), Woolloongabba
The Townsville Hospital ( Site 0404), Douglas
Haukeland Universitetssykehus ( Site 0902), Bergen
Hopital La Timone ( Site 0603), Marseille
Fox Chase Cancer Center ( Site 0351), Philadelphia
Lombardi Comprehensive Cancer Center ( Site 0360), Washington D.C.
Universitaets-Hautklinik Kiel ( Site 0656), Kiel
Hospital Universitario Ramon y Cajal ( Site 0753), Madrid
Medizinische Hochschule Hannover ( Site 0652), Hanover
Centro Estatal de Cancerologia de Chihuahua ( Site 0308), Chihuahua City
IUCT - Oncopole ( Site 0604), Toulouse
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0301), Guadalajara
Universitaetsklinikum Essen ( Site 0650), Essen
Hospital General de Valencia ( Site 0752), Valencia
Indiana University Melvin and Bren Simon Cancer Center ( Site 0353), Indianapolis
CHU Reims - Hopital Robert Debre ( Site 0610), Reims
Sanford Cancer Center Oncology Clinic ( Site 0356), Sioux Falls
CHRU Lille - Hopital Claude Huriez ( Site 0605), Lille
Hospital y Clinica OCA SA de CV/Monterrey International ResearchCenter ( Site 0306), Monterrey
University of Kansas Cancer Center ( Site 0361), Westwood
Universitaetsklinikum Mannheim GmbH ( Site 0654), Mannheim
CH Lyon Sud Hospices Civils de Lyon ( Site 0600), Pierre-Bénite
Universitatsklinikum Tübingen ( Site 0651), Tübingen
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0364), Tulsa
Hopital Saint-Louis ( Site 0601), Paris
Texas Oncology PA ( Site 8000), Dallas
CHU Limoges CHU Dupuytren ( Site 0608), Limoges
Comprehensive Cancer Centers of Nevada ( Site 8001), Las Vegas
Hopital Avicenne ( Site 0609), Bobigny
Stanford University Medical Center ( Site 0366), Palo Alto
Institut Gustave Roussy (IGR) ( Site 0602), Villejuif
St. Joseph Heritage Healthcare ( Site 0350), Santa Rosa
Rambam Health Care Campus ( Site 0950), Haifa
Rabin Medical Center ( Site 0952), Petah Tikva
Sheba Medical Center ( Site 0953), Ramat Gan
Sourasky Medical Center. ( Site 0951), Tel Aviv
Moores UC San Diego Cancer Center ( Site 0352), La Jolla
Yale University ( Site 0365), New Haven
Massachusetts General Hospital ( Site 0362), Boston
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0367), Hackensack
Dr. Leon Richard Oncology Centre ( Site 0100), Moncton
The Ottawa Hospital Cancer Centre ( Site 0101), Ottawa
Sunnybrook Research Institute ( Site 0105), Toronto
Princess Margaret Cancer Centre ( Site 0102), Toronto
Jewish General Hospital ( Site 0103), Montreal
Hopital Archet 3 ( Site 0607), Nice
Grupo Medico Camino SC ( Site 0300), Mexico City
Oslo Universitetssykehus Radiumhospitalet ( Site 0901), Oslo
Hospital Duran i Reinals ICO de Hospitalet ( Site 0751), Hospitalet Del Llobregat
Hospital Vall D Hebron ( Site 0750), Barcelona
Hospital Clinic i Provincial Barcelona ( Site 0754), Barcelona
The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0803), Bebington
University College Hospital NHS Foundation Trust ( Site 0801), London
Royal Marsden NHS Foundation Trust ( Site 0800), London
Royal Cornwall Hospitals NHS Trust ( Site 0804), Truro
Merck Sharp & Dohme LLC
INDUSTRY